GlycoMimetics Alpha and Beta Analysis

GLYCDelisted Stock  USD 0.16  0.01  5.88%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as GlycoMimetics. It also helps investors analyze the systematic and unsystematic risks associated with investing in GlycoMimetics over a specified time horizon. Remember, high GlycoMimetics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to GlycoMimetics' market risk premium analysis include:
Beta
(155.38)
Alpha
152.71
Risk
0.0
Sharpe Ratio
0.0
Expected Return
0.0
Please note that although GlycoMimetics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, GlycoMimetics did 152.71  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of GlycoMimetics stock's relative risk over its benchmark. GlycoMimetics has a beta of 155.38  . As returns on the market increase, returns on owning GlycoMimetics are expected to decrease by larger amounts. On the other hand, during market turmoil, GlycoMimetics is expected to outperform it. .
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

GlycoMimetics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. GlycoMimetics market risk premium is the additional return an investor will receive from holding GlycoMimetics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in GlycoMimetics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate GlycoMimetics' performance over market.
α152.71   β-155.38

GlycoMimetics Fundamentals Vs Peers

Comparing GlycoMimetics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze GlycoMimetics' direct or indirect competition across all of the common fundamentals between GlycoMimetics and the related equities. This way, we can detect undervalued stocks with similar characteristics as GlycoMimetics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of GlycoMimetics' fundamental indicators could also be used in its relative valuation, which is a method of valuing GlycoMimetics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare GlycoMimetics to competition
FundamentalsGlycoMimeticsPeer Average
Return On Equity-1.83-0.31
Return On Asset-0.74-0.14
Current Valuation1 B16.62 B
Shares Outstanding64.53 M571.82 M
Shares Owned By Insiders2.66 %10.09 %
Shares Owned By Institutions47.76 %39.21 %
Number Of Shares Shorted1.71 M4.71 M

GlycoMimetics Opportunities

GlycoMimetics Return and Market Media

The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Cantor Fitzgerald Initiates Coverage on GlycoMimetics
03/21/2025
2
GlycoMimetics Amends Merger Agreement With Crescent Biopharma - Investing.com
04/29/2025
3
SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates PRA, FARO, AVDX, GLYC on Behalf of Shareholders
05/09/2025
4
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
05/29/2025
5
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related ...
06/05/2025
6
GameStop Posts Weak Revenue, Joins American Superconductor, GitLab And Other Big Stocks Moving Lower In Wednesdays Pre-Market Session
06/11/2025

About GlycoMimetics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including GlycoMimetics or other delisted stocks. Alpha measures the amount that position in GlycoMimetics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

GlycoMimetics Upcoming Company Events

As portrayed in its financial statements, the presentation of GlycoMimetics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GlycoMimetics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of GlycoMimetics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of GlycoMimetics. Please utilize our Beneish M Score to check the likelihood of GlycoMimetics' management manipulating its earnings.
3rd of April 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with GlycoMimetics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Consideration for investing in GlycoMimetics Stock

If you are still planning to invest in GlycoMimetics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GlycoMimetics' history and understand the potential risks before investing.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Transaction History
View history of all your transactions and understand their impact on performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios